5445-73-8

Usage

Uses

Used in Pharmaceutical Research and Development:
2-(METHYLTHIO)-1,4,5,6-TETRAHYDROPYRIMIDINE HYDROIODIDE is used as a potential drug candidate for the treatment of various diseases, leveraging its stability and solubility in the hydroiodide form, which facilitates research and formulation development.
Used in Neurological Applications:
In the field of neurology, 2-(METHYLTHIO)-1,4,5,6-TETRAHYDROPYRIMIDINE HYDROIODIDE is used as a target for drug discovery due to its neuroprotective properties, which may contribute to the development of treatments for neurological disorders.
Used in Anticonvulsant Medications:
2-(METHYLTHIO)-1,4,5,6-TETRAHYDROPYRIMIDINE HYDROIODIDE is utilized as a compound with anticonvulsant properties, indicating its potential use in the development of medications for the treatment of seizure disorders.

InChI:InChI=1/C5H10N2S.HI/c1-8-5-6-3-2-4-7-5;/h2-4H2,1H3,(H,6,7);1H

Upstream product

• 2055-46-1 3,4,5,6-tetrahydropyrimidine-2-thione 
• 74-88-4 methyl iodide 
• 2055-46-1 2-mercapto-3,4,5,6-tetrahydropyrimidine 

Downstream Products

• 1852-17-1 3,4,5,6-tetrahydropyrimidin-2(1H)-one 
• 1403665-44-0 (4-methoxybenzyl)(1,4,5,6-tetrahydropyrimidin-2-yl)amine hydroiodide 
• 689259-78-7 (2,2-Dimethyl-3-{3-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)propoxy]-phenyl}cyclopropyl)Acetic Acid 
• 689259-69-6 (2-{4-[3-(1,4,5,6-Tetrahydropyrimidin-2-ylamino)propoxy]phenyl}-cyclopropyl)Acetic Acid 
• 192945-03-2 3-({1-[3-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-propyl]-1H-indazole-5-carbonyl}-amino)-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid tert-butyl ester 
• 121568-15-8 (2-Fluoro-phenyl)-(2-methylsulfanyl-5,6-dihydro-4H-pyrimidin-1-yl)-methanone 
• 49541-79-9 2-Hydrazino-1,4,5,6-tetrahydropyrimidine monohydroiodide 
• 121568-34-1 (5-Chloro-2-nitro-phenyl)-(2-methylsulfanyl-5,6-dihydro-4H-pyrimidin-1-yl)-methanone 
• 121568-35-2 (5-Methyl-2-nitro-phenyl)-(2-methylsulfanyl-5,6-dihydro-4H-pyrimidin-1-yl)-methanone 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS

The invention provides compounds of formula Ia′, Ib′, Ic′, and Id′: and pharmaceutically acceptable salts thereof, wherein the variables A, R6, R7, R8, R9, Rx, L, X, Y, and Z have the meaning as described herein. The compounds are useful for reducing endoplasmic reticulum stress and for producing analgesia in an animal.

Synthesis of five- and six-membered cyclic guanidines by guanylation with isothiouronium iodides and amines under mild conditions

Cyclic guanidine hydroiodides were obtained in one step by the reactions of isothiouronium iodides with an equimolar amount of various amines in tetrahydrofuran. The obtained hydroiodides were neutralized with sodium hydroxide or anionic exchange resin to afford the corresponding substituted cyclic guanidines in quantitative yields.

Synthesis, antihistaminic action and theoretical studies of (4-methoxybenzyl)(1,4,5,6-tetrahydropirimidin-2-yl)amine hydroiodide

In this study, (4-methoxybenzyl)(1,4,5,6-tetrahydropyrimidin-2-yl)amine hydroiodide (2) was synthesized by reaction of 2-methylmercapto-1,4,5,6- tetrahydropyrimidine hydroiodide (1) and 4-methoxybenzylamine. The synthesized compound was tested for its in vitro H1-antihistaminic activity on guinea pig trachea. A promising bronchorelaxant effect of 2 was observed in histamine-contracted guinea pig tracheal chain via H1 receptor antagonism. In addition, the molecular geometry and gauge including atomic orbital (GIAO) 1H chemical shift values of the title compound in the ground state were calculated using the density functional method (DFT/UB3LYP) and Hartree-Fock (HF) approach using 6-311G+(d), 6-311G+(d,p), LANL2DZ, DGDZVP, and DGDZVP2 basis sets and compared with the experimental data. According to the experimental and theoretical results, HF/6-311G+(d) showed a better fit to experimental values in evaluating 1H-nuclear magnetic resonance (NMR) chemical shift values. Theoretical studies supported our findings, revealing the N12 atom as the most nucleophilic. In addition, other structures of the compound such as the aromatic ring and OCH3 group increased this property.

Potent antimalarial activity of 2-aminopyridinium salts, amidines, and guanidines

We describe the design, synthesis, and antimalarial activity of 60 bis-tertiary amine, bis-2(1H)-imino-heterocycle, bis-amidine, and bis-guanidine series. Bis-tertiary amines with a linker from 12 to 16 methylene groups were active against the in vitro growth of Plasmodium falciparum within the 10 -6-10-7 M concentration range. IC50 decreased by 2 orders of magnitude for bis-2-aminopyridinium salts, bis-amidines, and bis-guanidines (27 compounds with IC50 a over 12.5. Maximal activity occurs for bis-2-aminopyridinium, two C-duplicated bis-amidines, and three bis-guanidines, with IC50 values lower than 1 nM. In comparison to similar quaternary ammonium salts, amidinium compounds have distinct structural requirements for antimalarial activity and likely additional binding opportunities on account of their hydrogen-bond-forming properties.

Compounds with antiparasitic activity and medicines containing same

The invention relates to compounds having an anti-parasitic, in particular antimalarial activity, characterized in that they correspond to general formula (I) Applications in particular as compounds with anti-parasitic activity.

PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS

The invention is directed to piperidinyl compounds of formula (I) and (II) that selectively bind integrin receptors and methods for treating an integrin mediated disorder, wherein W, R2, Z and q are described in the application.

Solution parallel synthesis of cyclic guanidines

An efficient method for the solution phase synthesis of cyclic guanidines is presented. A variety of 2-substituted monoprotected propanediamines react with a set of 5-substituted 2-methylthio-3,4,5,6- tetrahydropyrimidines under Rathke conditions for the construction of a potential library of 81 cyclic guanidines.

Potent gonadotropin releasing hormone antagonists with low histamine- releasing activity

The incorporation of Arg residues into position 6 of gonadotropin releasing hormone antagonists had resulted in compounds with increased in vivo potency but also made these analogues potent mast cell degranulators. We have focused on the substitution of position 8 by hArg(R)2 (N(G)-N(G)'- dialkylhomoarginine) substitutions, based on the hypotheses that the Arg-Pro sequence is of major importance for this side effect and that shielding of the charge may be an effective way to block degranulation. Analogues in four series were evaluated: (A) [N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Pal- (3)3,6,Arg5,hArg(R)28,D-Ala10]GnRH, (B) [N-Ac-D-Nal(2)1,D-pCl- Phe2,D-Pal(3)3,6,hArg(R)25,8,D-Ala10]-GnRH, (C) [N-Ac-D-Nal(2)1,D- pCl-Phe2,D-Pal(3)3,6,hArg(R)28,D-Ala10]GnRH, (D) [N-Ac-D-Nal(2)1,D- pCl-Phe2,D-Pal(3)3,D-hArg(R)26,hArg(R)28,D-Ala10]GnRH. Although substitution by hArg(Et)2, hArg(Bu), hArg(CH2)3, and hArg(CH2CF3)2 was tested, in each series the hArg(Et)2 residue was superior. Two compounds were considered for clinical evaluation: [N-Ac-D-Nal(2)1,D-pCl-Phe2,D- Pal(3)3,6,hArg(Et)28,D-Ala10]GnRH and [N-Ac-D-Nal(2)1,D-pCl-Phe2,D- Pal(3)3,D-hArg(Et)26,hARg-(Et)28,D-Ala10]GnRH (ganirelix acetate). These compounds had high potency for ovulation suppression and low histamine- releasing potency in vitro (ED50 = 0.6, 0.29 μg/rat and EC50 = 196, 13 μg/mL, respectively). Ganirelix is currently in Phase II clinical trials and appears to be the most potent GnRH antagonist tested in humans (based upon ED50 for 24-h suppression of testosterone levels).